DG DISPATCH - APA: Vagus Nerve Stimulation for Treatment-Resistant Depression
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




DG DISPATCH - APA: Vagus Nerve Stimulation for Treatment-Resistant Depression

By Lara Pullen
Special to DG News

CHICAGO, IL -- May 18, 2000 -- Long-term vagus nerve stimulation (VNS) appears to be a safe and effective treatment for a significant number of patients with severe, treatment-resistant depression.

VNS stimulation is an approved form of therapy for treatment-resistant epilepsy and requires surgery and the "wearing" of a palm-sized stimulator.

At the 2000 Annual Meeting of the American Psychiatric Association, in Chicago, IL, Lauren B. Marangell, MD, of Baylor College of Medicine, Houston, TX, presented the results of an open trial of the effects of VNS on depression.

The trial included 30 outpatients with non-psychotic, major depressive disorder (n=21), bipolar I disorder (n=4), or bipolar II depressed phase disorder (n=5). These patients were in a current major depressive episode for two years or more or had four or more major depressive episodes in their lifetime.

Patients in the study were allowed to take stable psychotropic medication regimens.

There were 11 acute phase responders, of whom 91 percent maintained response at nine months. There were 16 acute phase non-responders, of whom 38 percent were responders by nine months.

Data for the nine-month visit were not available for one acute phase responder and two acute phase non-responders.

Any physicians interested in participating in the extension of the pilot study should phone the Physician Referral Line at 1-888-748-1657.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities